Page 75 - Lipids News Today

"Go early and go low" is an experts response to the imaging results from PACMAN-AMI showing plaque reduction after AMI patients received alirobumab.

In patients with angina and no coronary artery disease, 6 weeks of diltiazem did not improve coronary function test results, apart from epicardial spasm, or angina symptoms in the EDIT-CMD trial.

While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or "bad" cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of heart disease risk.

The selling point of percutaneous left atrial appendage occlusion is to prevent stroke while avoiding the bleeding risk of antithrombotics. The data paint a different picture, writes John Mandrola, MD.

Lipid and fatty acid traits may be implicated in early Alzheimers disease, and could signal treatment targets.

An investigational antisense oligonucleotide drug targeting a novel cholesterol pathway showed disappointing results in this phase 2b study.

They include new generalist-friendly labels for the traditional but obscurely named four stages of HF that, it is hoped, will have wider reach and expand the use of effective therapies.

The results add to growing enthusiasm for achieving the holy grail of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.

Trial results for the twincretin in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the SGLT2 inhibitors.

Meeting guideline-recommended exercise targets lowers risk of CVD in everyone, but even more so in patients with anxiety or depression, new research shows.